Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of lumateperone monotherapy for depressive episodes with mixed features in bipolar disorder or major depressive disorder
2019-004440-29Phase 3Completed
- Sponsor
- Intra-Cellular Therapies
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bipolar disorder (BD) and major depressive disorder (MDD) comparing Lumateperone monotherapy with Placebo (2 arms). Primary endpoint: Change from baseline to Day 43 in MADRS total score. Started May 2020; status: completed.
02
Drugs
lumateperone
03
Conditions
bipolar disorder (BD)major depressive disorder (MDD)
Beyond the preview
Go deeper on 2019-004440-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004440-29.